Patent ID: 11938180
Assignee: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE, MINISTERIAL CORRESPONDENCE AND PUBLIC ENQUIRIES, DEPARTMENT OF HEALTH AND SOCIAL CARE
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 7:
8. The poliovirus-like particle (VLP) of claim 5, wherein said one further modification in one or more additional structural domain is selected from the group consisting of:
(a) a VP2/VP3 interface serotype 1 capsid stabilising modification selected from the group consisting of: S1295P and I2197V; and/or
(b) an internal network serotype 1 capsid stabilising modification selected from the group consisting of: N4017T, S4023Y, F4046L, E4055Q and M1009V; and/or
(c) a canyon serotype 1 capsid stabilising modification selected from the group consisting of: M1090L and K1252T; and/or
(d) a VP1/VP2 interface serotype 1 capsid stabilising modification selected from the group consisting of: V2127I; and/or
(e) an other serotype 1 capsid stabilising modification selected from the group consisting of: A3059D, G2159S, S2168A and G2228V; and/or
(f) a VP2/VP3 interface serotype 2 capsid stabilising modification selected from the group consisting of: I2191V; and/or
(g) an internal network serotype 2 capsid stabilising modification selected from the group consisting of: E4055A, E4055Q, I4057L, I4057V, V2033I, Q3161E and L1021P; and/or
(h) a canyon serotype 2 capsid stabilising modification selected from the group consisting of: M2140T; and/or
(i) an other serotype 2 capsid stabilising modification selected from the group consisting of: T2161S, R3094K and R1100C; and/or
(j) an internal network serotype 3 capsid stabilising modification selected from the group consisting of: E4055Q, M2124I, A1054V, A1054T, V1265I and I1075V; and/or
(k) an external (protomer near interface) serotype 3 capsid stabilising modification selected from the group consisting of: K2269R.